Analisis Keuangan Saham GTBP - GT Biopharma, Inc. (NasdaqCM) Stock

Gambaran Umum

GT Biopharma, Inc. is a U.S.-based biotechnology company primarily engaged in the development of immune-oncology products. The company employs its proprietary NK cell engager (TriKE) platform technology to develop novel therapeutics targeting cancerous tumors. A key project in its pipeline includes treatments focusing on various cancers, such as breast cancer and myeloid leukemias, by utilizing immune cells to precisely attack and destroy cancer cells while minimizing damage to normal tissues. GT Biopharma's research aims to harness the power of natural killer (NK) cells to enhance the immune system's response to malignancies, representing a significant advancement in the field of oncology treatment. This strategic focus underlines the company's commitment to innovation in cancer therapy development.

Skor Kualitas, Nilai, dan Momentum

Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.

Kualitas

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Nilai

Model penilaian eksklusif yang memberi peringkat pada perusahaan berdasarkan valuasi relatifnya. Skor berkisar antara 0 hingga 100, dengan 100 sebagai yang paling diremehkan nilainya.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Sentimen Dana

Skor Sentimen Dana (sebelumnya dikenal sebagai Skor Kepemilikan) adalah model kuantitatif eksklusif yang memberi peringkat pada perusahaan berdasarkan tingkat akumulasi kepemilikan.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih

Nilai operating income untuk GT Biopharma, Inc. per 2025 Jun 30 adalah -10.81 MM.
Nilai net income untuk GT Biopharma, Inc. per 2025 Jun 30 adalah -9.39 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30		-10.81	-9.39
2025-03-31		-13.21	-11.67
2024-12-31		-14.36	-13.16
2024-09-30		-13.77	-12.35
2024-06-30		-13.29	-11.35
2024-03-31		-13.00	-9.64
2023-12-31		-13.58	-7.60
2023-09-30		-16.19	-10.22
2023-06-30		-20.09	-14.68
2023-03-31		-19.48	-15.67
2022-12-31		-21.26	-20.88
2022-09-30		-33.66	-33.32
2022-06-30		-32.59	-31.89
2022-03-31		-33.95	-33.78
2021-12-31		-57.52	-58.01
2021-09-30		-41.53	-46.28
2021-06-30		-37.52	-43.70
2021-03-31		-34.70	-56.27
2020-12-31		-6.76	-28.30
2020-09-30		-5.44	-23.48
2020-06-30
2020-03-31

Laporan Laba Rugi: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31	-6.94
2024-09-30	-7.36	-7.36
2024-06-30	-7.77	-7.77
2024-03-31	-6.78	-6.78
2023-12-31	-5.64
2023-09-30	-8.04	-8.09
2023-06-30	-12.32	-12.43
2023-03-31	-14.75	-14.75
2022-12-31	-19.66
2022-09-30	-30.77	-30.70
2022-06-30	-30.25	-30.13
2022-03-31	-31.45	-31.45
2021-12-31	-61.81
2021-09-30	-67.31	-67.31
2021-06-30	-88.83	-88.83
2021-03-31	-227.65	-227.65
2020-12-31	-193.58
2020-09-30	-166.90	-166.90
2020-06-30	-382.74	-382.74
2020-03-31	-293.56	-292.84

Arus Kas: Operasi, Investasi, Pendanaan

Nilai cash from operating activities untuk GT Biopharma, Inc. per 2025 Jun 30 adalah -10.42 MM.
Nilai cash from investing activities untuk GT Biopharma, Inc. per 2025 Jun 30 adalah 0.00 MM.
Nilai kas dari aktivitas pendanaan untuk GT Biopharma, Inc. per 2025 Jun 30 adalah 6.49 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-10.42	0.00	6.49
2025-03-31	-10.94	7.86	3.59
2024-12-31	-12.90	12.89	2.98
2024-09-30	-12.48	13.37	2.98
2024-06-30	-11.71	15.22	2.98
2024-03-31	-10.11	10.01	0.00
2023-12-31	-8.85	-2.01	6.27
2023-09-30	-11.10	5.02	6.27
2023-06-30	-12.06	3.20	6.27
2023-03-31	-12.91	1.62	6.04
2022-12-31	-15.22	12.14	-0.22
2022-09-30	-14.62	7.63	-0.22
2022-06-30	-15.63	-18.43	-0.09
2022-03-31	-17.14	-19.51	16.38
2021-12-31	-15.61	-23.04	42.32
2021-09-30	-13.83	-26.03	49.19
2021-06-30	-11.60		50.25
2021-03-31	-10.72		38.27
2020-12-31	-7.26		12.53
2020-09-30	-5.82	0.00	5.86
2020-06-30
2020-03-31

Metrik Penilaian: PE, PriceToBook, PriceToTBV

p/libro untuk GT Biopharma, Inc. pada 2025 Jun 30 adalah -9.27.
p/tbv untuk GT Biopharma, Inc. pada 2025 Jun 30 adalah -9.26.

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30		-9.27	-9.26
2025-03-31	-0.40	-3.13	-3.13
2024-12-31		3.25	3.25
2024-09-30	-0.42	0.86	0.86
2024-06-30	-0.63	1.14	1.14
2024-03-31	-0.81	0.83	0.83
2023-12-31	-1.03	1.05	1.05
2023-09-30	-0.65	0.82	0.82
2023-06-30	-0.54	0.95	0.95
2023-03-31	-0.83	1.47
2022-12-31		1.81	1.81
2022-09-30		3.62	3.62
2022-06-30	-2.68	5.09	5.09
2022-03-31	-1.59	4.22	4.22
2021-12-31	-2.00	2.91	2.91
2021-09-30	-4.72	5.69	5.69
2021-06-30
2021-03-31	-0.77	1.80	1.80
2020-12-31	-0.39	-0.37	-0.37
2020-09-30	-0.41	-0.32	-0.32
2020-06-30	-0.19	-0.34	-0.34
2020-03-31	-0.24	-0.42	-0.42

Metrik Penilaian: EBitToEv, EBit3YrAvgToEv

EBIT/EV untuk GT Biopharma, Inc. pada 2025 Jun 30 adalah -1.74.
EBIT (3 tahun) / EV untuk GT Biopharma, Inc. pada 2025 Jun 30 adalah -1.87.

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30	-1.74	-1.87
2025-03-31	-10.30	-10.03
2024-12-31	-31.05	-34.22
2024-09-30	2.50	4.04
2024-06-30	-2.33	-4.77
2024-03-31	-1.49	-5.65
2023-12-31	-1.30	-3.82
2023-09-30	-2.15	-4.41
2023-06-30	-3.78	-5.83
2023-03-31	-1.80	-3.18
2022-12-31	-1.26	-1.30
2022-09-30	-0.63	-0.67
2022-06-30	-0.41	-0.51
2022-03-31	-0.69	-0.60
2021-12-31	-0.56	-0.46
2021-09-30	-0.26	-0.22
2021-06-30
2021-03-31	-3.61	-7.39
2020-12-31	-0.89	-3.41
2020-09-30	-0.73	-3.37
2020-06-30	-1.67	-4.99
2020-03-31	-1.64	-6.67

Efektivitas Manajemen

roa untuk GT Biopharma, Inc. pada 2025 Jun 30 adalah -1.26.
roe untuk GT Biopharma, Inc. pada 2025 Jun 30 adalah -2.12.

Period End (TTM)	ROA	ROE	ROIC (Tingkat Pengembalian Investasi Modal)	CROIC	OCROIC
2025-06-30	-1.26	-2.12
2025-03-31	-1.33	-2.48
2024-12-31	-0.88	-1.65	-5.89	1.84	-5.95
2024-09-30	-0.70	-1.13	-2.05	1.17	-2.11
2024-06-30	-0.48	-0.74	-1.80	-0.02	-1.89
2024-03-31	-0.45	-0.65	-1.01	-0.61	-1.17
2023-12-31	-0.48	-0.64	-1.01	0.02	-1.10
2023-09-30	-0.61	-0.95	-1.24	-0.22	-1.01
2023-06-30	-0.86	-1.35	-1.23	-0.22	-1.01
2023-03-31	-0.76	-1.17	-1.19	-0.40	-0.98
2022-12-31	-0.93	-1.05	-2.06	-0.45	-0.91
2022-09-30	-0.89	-1.00	-2.06	-0.45	-0.91
2022-06-30	-0.85	-0.93	-2.03	-2.18	-1.00
2022-03-31	-2.10	-2.42	-1.87	-1.12	-0.95
2021-12-31	-8.18		-2.64	0.17	-0.43
2021-09-30	-47.66		-1.45	0.29	-0.32
2021-06-30	-41.11		-1.20	1.06	-0.32
2021-03-31	-190.73		-2.33	1.14	-0.44
2020-12-31	-71.45	1.47
2020-09-30	-48.71
2020-06-30	-1.96	-5.62
2020-03-31	-1.40	-3.58

Gross Margins

Margin Kotor: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Margin Keuntungan Bersih: Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.

Margin Operasi: Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.

Period End (TTM)	Margin Kotor	Margin Keuntungan Bersih	Margin Operasi
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31